For the quarter ending 2025-09-30, CARL had $81,901K increase in cash & cash equivalents over the period. -$8,618K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,526 | -12,495 |
| Depreciation and amortization | 82 | 101 |
| Stock-based compensation | 704 | 433 |
| Non-cash interest | 55 | 108 |
| Loss on remeasurement of warrant liabilities | 65 | 270 |
| Non-cash lease expense | 157 | 219 |
| Provision for credit losses | 24 | 338 |
| Provision for excess and obsolete inventory | 465 | 872 |
| Other non-cash items | -17 | - |
| Accounts receivable, net | 1,611 | 3,282 |
| Inventory | 736 | 945 |
| Prepaid expenses and other assets | 1,638 | 500 |
| Accounts payable | 682 | 1 |
| Accrued liabilities | 608 | -78 |
| Accrued compensation | 1,296 | -157 |
| Lease liabilities | -103 | -82 |
| Net cash used in operating activities | -8,459 | -15,197 |
| Purchase of property and equipment | 159 | 410 |
| Capitalized internal use software costs | 184 | 374 |
| Payment of initial direct costs related to operating leases | 0 | 126 |
| Net cash used in investing activities | -343 | -910 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 93,465 | - |
| Payments for deferred initial public offering costs | 2,763 | 2,648 |
| Proceeds from issuance of series c convertible preferred stock, net of issuance costs | 0 | 11,919 |
| Proceeds from exercises of stock options | 1 | 183 |
| Net cash provided by financing activities | 90,703 | 9,454 |
| Increase in cash, cash equivalents, and restricted cash | 81,901 | -6,653 |
| Cash and cash equivalents at beginning of period | 40,225 | - |
| Cash and cash equivalents at end of period | 115,473 | - |
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)